A hybrid multistage protein vaccine induces protective immunity against murine malaria

Infection and Immunity

Volumn 80, Issue 4, 2012, Pages 1491-1501

  Singh, Balwan ^a   Cabrera Mora, Monica ^a   Jiang, Jianlin ^a   Moreno, Alberto ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; MULTISTAGE PROTEIN; NEUTRALIZING ANTIBODY; PLASMODIUM YOELII LINEAR PEPTIDE CHIMERA PROTEIN; PLASMODIUM YOELII RECOMBINANT MODULAR CHIMERA PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PLASMODIUM YOELII INFECTION; PRIORITY JOURNAL; SPOROZOITE; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; MALARIA; PATHOGENICITY; PLASMODIUM YOELII; RABBIT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNIZATION, PASSIVE; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; PLASMODIUM YOELII; PROTOZOAN PROTEINS; RABBITS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860797417     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05980-11     Document Type: Article

References (33)

1. Bentley GA. 2006. Functional and immunological insights from the three-dimensional structures of Plasmodium surface proteins. Curr. Opin. Microbiol. 9:395-400.
2. Caro-Aguilar I, Lapp S, Pohl J, Galinski MR, Moreno A. 2005. Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria. Microbes Infect. 7:1324-1337.
3. Caro-Aguilar I, et al. 2002. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infect. Immun. 70:3479-3492.
4. Casares S, Brumeanu T-D, Richie TL. 2010. The RTS,S malaria vaccine. Vaccine 28:4880-4894.
5. Charoenvit Y, et al. 1999. CD4+ T-cell-and gamma interferondependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect. Immun. 67:5604-5614.
6. Chitarra V, Holm I, Bentley GA, Petres S, Longacre S. 1999. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol. Cell 3:457-464.
7. Cunha MG, Rodrigues MM, Soares IS. 2001. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP119 expressed in distinct bacterial vectors. Vaccine 20:385-396.
8. Darrah PA, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
9. de Cassan SC, et al. 2011. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J. Immunol. 187:2602-2616.
10. Del Giudice G, et al. 1990. Peptide-primed CD4+ cells and malaria sporozoites. Immunol. Lett. 25:59-63.
11. Douglas AD, et al. 2010. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28:7167-7178.
12. Draper SJ, et al. 2009. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody-and T cell-mediated multistage protection against malaria. Cell Host Microbe 5:95-105.
13. Forbes EK, et al. 2011. Combining liver-and blood-stage malaria viralvectored vaccines: investigating mechanisms of CD8+T cell interference. J. Immunol. 187:3738-3750.
14. Goodman AL, et al. 2010. New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect. Immun. 78:4601-4612.
15. Hensmann M, et al. 2004. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur. J. Immunol. 34:639-648.
16. Nardin EH, et al. 1982. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156: 20-30.
17. Pichyangkul S, et al. 2009. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28:452-462.
18. Pizarro JC, et al. 2003. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J. Mol. Biol. 328: 1091-1103.
19. Pusic KM, et al. 2011. T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. PLoS One 6:e24782.
20. Roederer M, Nozzi JL, Nason MC. 2011. SPICE: exploration and analysis of postcytometric complex multivariate datasets. Cytometry A 79:167-174.
21. Roestenberg M, et al. 2009. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361:468-477.
22. Roestenberg M, et al. 2011. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377:1770-1776.
23. Sacci JB, Jr et al. 2005. Transcriptional analysis of in vivo Plasmodium yoelii liver stage gene expression. Mol. Biochem. Parasitol. 142:177-183.
24. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247-258.
25. Shi Q, Lynch MM, Romero M, and Burns JM, Jr. 2007. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect. Immun. 75:1349-1358.
26. Silva-Flannery LM, Cabrera-Mora M, Jiang J, Moreno A. 2009. Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine. Microbes Infect. 11:83-91.
27. Singh B, Cabrera-Mora M, Jiang J, Galinski M, Moreno A. 2010. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate. Vaccine 28:2580-2592.
28. Stephens R, et al. 2005. Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance. Blood 106:1676-1684.
29. Vidor E. 2007. The nature and consequences of intra-and inter-vaccine interference. J. Comp. Pathol. 137:S62-S66.
30. Wang R, et al. 1996. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+T cell-and IFN-gamma-dependent elimination of infected hepatocytes. J. Immunol. 157:4061-4067.
31. Weiss W, et al. 1990. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J. Exp. Med. 171:763-773.
32. WHO. 2011. World malaria report 2011. World Health Organization, Geneva, Switzerland.
33. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73.